XML 21 R10.htm IDEA: XBRL DOCUMENT
v3.21.1

Collaborative Arrangements | 3 Months Ended
--- | ---
Mar. 31, 2021
Collaborative Arrangements [Abstract] |
Collaborative Arrangements | Collaborative Arrangements Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below. AstraZeneca In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly (ADP-ribose) polymerase (PARP) inhibitor currently approved for certain types of advanced ovarian, breast, pancreatic and prostate cancers. The companies are jointly developing and commercializing Lynparza, both as monotherapy and in combination trials with other potential medicines. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib), an oral, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway for multiple indications. In April 2020, Koselugo was approved by the FDA for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities. Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. Merck will fund all development and commercialization costs of Keytruda in combination with Lynparza or Koselugo. AstraZeneca will fund all development and commercialization costs of Imfinzi in combination with Lynparza or Koselugo. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of Research and development expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs. As part of the agreement, Merck made an upfront payment to AstraZeneca and made payments over a multi-year period for certain license options. In addition, the agreement provides for additional contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. Prior to 2021, Merck accrued sales-based milestone payments aggregating $1.4 billion related to Lynparza, of which $1.0 billion was paid to AstraZeneca. Potential future sales-based milestone payments of $2.7 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. Prior to 2021, Lynparza received regulatory approvals triggering capitalized milestone payments of $360 million in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.4 billion remain under the agreement. The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.2 billion at March 31, 2021 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing. Summarized financial information related to this collaboration is as follows:
| Three Months Ended March 31, |  |
($ in millions) | 2021 |  | 2020 |  |  |  |
Alliance revenue - Lynparza | $ | 228 |  |  | $ | 145 |  |  |  |  |
Alliance revenue - Koselugo | 5 |  |  | — |  |  |  |  |
Total alliance revenue | $ | 233 |  |  | $ | 145 |  |  |  |  |
Cost of sales (1) | 42 |  |  | 28 |  |  |  |  |
Selling, general and administrative | 40 |  |  | 33 |  |  |  |  |
Research and development | 29 |  |  | 36 |  |  |  |  |
($ in millions) | March 31, 2021 |  | December 31, 2020 |  |  |  |
Receivables from AstraZeneca included in Other current assets | $ | 236 |  |  | $ | 215 |  |  |  |  |
Payables to AstraZeneca included in Accrued and other current liabilities (2) | 417 |  | 423 |  |  |  |
(1) Represents amortization of capitalized milestone payments. (2) Includes accrued milestone payments. Eisai In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Lenvima is currently approved for the treatment of certain types of thyroid cancer, hepatocellular carcinoma, in combination with everolimus for certain patients with renal cell carcinoma, and in combination with Keytruda for the treatment of certain patients with endometrial carcinoma. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions), and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in Research and development expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of Keytruda and Lenvima. Under the agreement, Merck made an upfront payment to Eisai of $750 million in 2018 and agreed to make payments of up to $650 million for certain option rights through 2021 (of which $325 million was paid in March 2019, $200 million was paid in March 2020 and $125 million was paid in March 2021). The upfront payment and license option payments were reflected in Research and development expenses in 2018. In addition, the agreement provides for additional contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. Prior to 2021, Merck accrued sales-based milestone payments aggregating $1.35 billion. Of these amounts, $550 million was paid to Eisai prior to 2021 and an additional $200 million was paid in the first quarter of 2021. Potential future sales-based milestone payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. Prior to 2021, Lenvima received regulatory approvals triggering capitalized milestone payments of $260 million in the aggregate from Merck to Eisai. Potential future regulatory milestone payments of $125 million remain under the agreement. The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $1.0 billion at March 31, 2021 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing. Summarized financial information related to this collaboration is as follows:
| Three Months Ended March 31, |  |
($ in millions) | 2021 |  | 2020 |  |  |  |
Alliance revenue - Lenvima | $ | 130 |  |  | $ | 128 |  |  |  |  |
Cost of sales (1) | 47 |  |  | 35 |  |  |  |  |
Selling, general and administrative | 23 |  |  | 11 |  |  |  |  |
Research and development | 64 |  |  | 64 |  |  |  |  |
($ in millions) | March 31, 2021 |  | December 31, 2020 |  |  |  |
Receivables from Eisai included in Other current assets | $ | 153 |  |  | $ | 157 |  |  |  |  |
Payables to Eisai included in Accrued and other current liabilities (2) | 300 |  |  | 335 |  |  |  |  |
Payables to Eisai included in Other Noncurrent Liabilities (3) | 300 |  |  | 600 |  |  |  |  |
(1) Represents amortization of capitalized milestone payments. (2) Includes accrued milestone and future option payments. (3) Includes accrued milestone payments. Bayer AG In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat), which is approved to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The two companies have implemented a joint development and commercialization strategy. The collaboration also includes clinical development of Bayer’s Verquvo (vericiguat), which was approved by the FDA in January 2021 to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults. Verquvo is under review by regulatory authorities in other territories including the EU and Japan. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the United States and Bayer will commercialize in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. In addition, the agreement provides for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. Prior to 2021, Merck paid $725 million of sales-based milestone payments to Bayer related to this collaboration. In the first quarter of 2021, following the approval of Verquvo noted above, Merck determined it was probable that sales of Adempas and Verquvo in the future would trigger the remaining $400 million sales-based milestone payment. Accordingly, Merck recorded a liability of $400 million and a corresponding increase to the intangible assets related to this collaboration in the first quarter of 2021. Merck also recognized $153 million of cumulative amortization expense related to the recognition of this milestone in the first quarter of 2021. The intangible asset balance related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) was $946 million at March 31, 2021 and is being amortized over its estimated useful life through 2027 as supported by projected future cash flows, subject to impairment testing. The intangible asset balance related to Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) was $76 million at March 31, 2021 and is being amortized over its estimated useful life through 2031 as supported by projected future cash flows, subject to impairment testing. Summarized financial information related to this collaboration is as follows:
| Three Months Ended March 31, |  |
($ in millions) | 2021 |  | 2020 |  |  |  |
Alliance revenue - Adempas | $ | 74 |  |  | $ | 53 |  |  |  |  |
Net sales of Adempas recorded by Merck | 55 |  |  | 56 |  |  |  |  |
Total sales | $ | 129 |  |  | $ | 109 |  |  |  |  |
Cost of sales (1) | 189 |  |  | 28 |  |  |  |  |
Selling, general and administrative | 32 |  |  | 15 |  |  |  |  |
Research and development | 7 |  |  | 25 |  |  |  |  |
($ in millions) | March 31, 2021 |  | December 31, 2020 |  |  |  |
Receivables from Bayer included in Other current assets | $ | 68 |  |  | $ | 65 |  |  |  |  |
Payables to Bayer included in Other Noncurrent Liabilities (2) | 400 |  |  | — |  |  |  |  |
(1) Includes amortization of intangible assets. Amount in the first quarter of 2021 includes $153 million of cumulative amortization as noted above. (2) Represents accrued milestone payment.

X
- Definition Collaborative Arrangements [Abstract] + References No definition available. + Details
Name: | mrk_CollaborativeArrangementsAbstract
Namespace Prefix: | mrk_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -URI http://asc.fasb.org/topic&trid=5833765 + Details
Name: | us-gaap_CollaborativeArrangementDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration